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OBJECTIVES: To evaluate the performance of fine and cutting needles in computed tomography guided-biopsy
of lung lesions suspicious for malignancy and to determine which technique is the best option for a specific
diagnosis.
METHODS: This retrospective study reviewed the data from 362 (71.6%) patients who underwent fine-needle
aspiration biopsy and from 97 (19.7%) patients who underwent cutting-needle biopsy between January 2006
and December 2011. The data concerning demographic and lesion characteristics, procedures, biopsy sample
adequacy, specific diagnoses, and complications were collected. The success and complication rates of both
biopsy techniques were calculated.
RESULTS: Cutting-needle biopsy yielded significantly higher percentages of adequate biopsy samples and
specific diagnoses than did fine-needle aspiration biopsy (p,0.05). The sensitivity, specificity, and accuracy of
cutting-needle biopsy were 93.8%, 97.3%, and 95.2%, respectively; those of fine-needle aspiration biopsy were
82.6%, 81.3%, and 81.8%, respectively (all p,0.05). The incidence of pneumothorax was higher for fine-needle
aspiration biopsy, and that of hematoma was higher for cutting-needle biopsy (both p,0.05).
CONCLUSIONS: Our experience using these two techniques for computed tomography-guided percutaneous
biopsy showed that cutting-needle biopsy yielded better results than did fine-needle aspiration biopsy and that
there was no significant increase in complication rates to indicate the best option for specific diagnoses.
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& INTRODUCTION
Computed tomography (CT)-guided percutaneous needle
biopsy (PNB) is a reliable technique for diagnosing thoracic
diseases, particularly for assessing lung lesions. Since the
first reported use of CT-guided biopsy, fine- and cutting-
needle biopsy techniques have improved diagnostic yields
and have reduced the risk of complications (1). Both
techniques yield satisfactory results with acceptable com-
plication rates; thus, the selection of needle type should be
based on factors related to the procedure, the biopsy
purpose, and the radiological lesion characteristics (2-4).
The type of needle is the most important source of
variation in biopsy techniques (5); fine-needle aspiration
biopsy (FNAB) uses cytological techniques for analysis,
whereas cutting-needle biopsy provides larger tissue sam-
ples that are suitable for histological evaluation (6,7). Nearly
all comparisons of FNAB and cutting-needle biopsy have
been based only on the capacity to differentiate between
benign and malignant lesions. In the contemporary oncolo-
gical context of personalized medicine, such preliminary
diagnoses are used only for staging purposes. Because up to
75% of the patients do not undergo surgical resection, tissue
specimens collected for therapeutic planning purposes
should allow for more complete diagnoses, including the
determination of biomarker profiles (8,9). Macrobiopsies
provide more adequate and high-quality tissue samples for
such purposes than do microbiopsies (i.e., FNABs) (10). The
objectives of this study were to compare the performance of
cutting and fine needles in CT-guided biopsies of lung
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lesions suspicious for malignancy with respect to the
capacity to obtain a specific diagnosis and to determine
which technique is optimal for cancer patient management.
& PATIENTS AND METHODS
This retrospective analysis included 434 consecutive
outpatients admitted to an oncology center between 2006
and 2011. These patients underwent 459 lung biopsies
employing either the cutting-needle (n = 97, 19.7%) or the
fine-needle (n = 362, 71.6%) technique.
Two inclusion criteria were considered: 1) the presence of
pulmonary lesions with CT characteristics suggestive of
malignancy; and 2) patients who were regularly admitted to
the hospital and followed in the institution. Because this
analysis was retrospective, no chest CT scan standardization
was performed. No patient had previously undergone CT-
guided biopsy that yielded inconclusive results; screening
coagulation tests were routinely ordered. We conducted this
study in compliance with the Declaration of Helsinki. The
Institutional Review Board approved this study, and the
requirement for informed patient consent was waived.
The data concerning the patients’ demographic character-
istics, adequacy of biopsy material, specific diagnoses, and
complications were collected from medical charts using the
hospital’s medical archive service. Information concerning
procedures and lesion characteristics (i.e., location, size,
number, contour, and depth) was collected from percuta-
neous biopsy forms. The radiological findings were
extracted from the reports of CT examinations performed
before biopsy.
The biopsies were performed using helical CT (HiSpeed,
General Electric Medical Systems, Milwaukee, WI, USA)
and standard techniques. In all of the patients, panoramic
scout images were acquired using 5- to 10-mm cuts to
specifically locate lesions and to compare their character-
istics with those found in previous examinations.
The patients’ charts and percutaneous biopsy forms did
not contain specific information concerning the reasons
underlying needle selection; the data were generally based
on lesion characteristics (e.g., size, depth, relationship to
vascular structures, and necrosis) and the patients’ clinical
condition. According to hospital protocol, fine needles are
typically used in critical patients and for smaller, deeper,
and potentially malignant lesions, and cutting needles are
used in stable patients and for larger, superficial lesions
with unknown malignancy status.
Patient preparation and lesion localization procedures
were similar for both needle types. The patients were
admitted after 6 hours of fasting in preparation for
anesthetics and, if needed, intravenous contrast adminis-
tration. All of the biopsies were performed using a helical
CT unit (HiSpeed, General Electric Medical Systems,
Milwaukee, WI, USA). CT was used to localize the
lesions and to guide needle insertion. The majority of the
procedures were performed under local anesthesia; how-
ever, several younger and uncooperative patients required
general anesthesia. The patients were positioned to allow
the most direct access to the lesions; when the lesions were
located in the thorax, passage through the aerated lung was
minimized to reduce the risk of pneumothorax.
For all of the procedures, local anesthesia using 1%
lidocaine was applied from the skin to the pleura following
the planned biopsy pathway. The needle was introduced
when the patient was in expiratory apnea, and new CT
scans were obtained to check (and modify, if necessary) the
needle’s position in relation to the lesion. The computer’s
cursor was used to measure the lesion’s dimensions and
distance to a metallic marker placed on the skin surface.
All of the procedures were repeated until the physician
determined that the sample obtained was macroscopically
appropriate.
FNABs were performed using 22-gauge Chiba-type
needles (Meditech, Gainesville, FL, USA). Biopsy sample
smears were prepared and immersed in 90% alcohol and
submitted to cytological evaluation for malignancy detec-
tion and, whenever possible, for a specific diagnosis.
Cutting-needle biopsies were performed using an auto-
mated 20-gauge coaxial system (Angiotech, Vancouver,
British Columbia, Canada). The needles were 10 cm or
15 cm in length, depending on the distance between the skin
and the lesion. The biopsy specimens were preserved in 10%
formalin and submitted to histological evaluation for a
specific diagnosis.
A pathologist routinely classified biopsy samples as
adequate (indicating procedural success) or inadequate
for analysis and as positive, negative, or suspicious for
malignancy. For technical reasons, this study did not
evaluate molecular profiles. Surgical biopsy or radiological
and clinical follow-up was considered to be the gold
standard for evaluating the sensitivity and specificity of
FNAB, and cutting-needle biopsy was used to determine the
presence of malignancy.
We defined a procedure-related complication as a new
radiological occurrence, such as pulmonary hematoma or
pneumothorax, on a post-biopsy CT image or a new (post-
biopsy) clinical symptom or sign, such as shortness of
breath, intense dyspnea, thoracic pain, or hemoptysis.
Success and complication rates were described according
to demographic, radiological, and procedure characteristics.
Descriptive analyses of demographic, clinical, radiologi-
cal, and pathological characteristics were performed.
Microsoft Excel 2000 software was used for collecting data
and for calculating correlations. All of the statistical analyses
were performed using SPSS software (version 17.0, SPSS) for
Microsoft Windows; p,0.05 was considered to indicate a
significant difference.
& RESULTS
Of 459 biopsies, 263 (57.3%) biopsies were performed in
male patients, and 196 (42.7%) biopsies were performed in
female patients. The patients’ mean age was 61¡16
(median, 63) years. The biopsies were performed either
due to the primary diagnosis of a focal lung lesion that was
suspicious for malignancy (FNAB, n= 215 [59.4%]; cutting
needle, n = 74 [76.3%]) or for the confirmation of metastasis
(FNAB, n = 147 [40.6%]; cutting needle, n = 23 [23.7%]).
In 180 (39.2%) cases, the patients had single lung lesions;
49 (10.7%) patients had two lung lesions, 34 (7.4%) patients
had three lung lesions, and 53 (11.5%) patients had four or
more lung lesions. Information on lesion number was not
available in 143 (31.2%) cases. Lung lesion diameters ranged
from 9 mm to 140 mm, with a mean diameter of
42.6¡24.3 mm and a median diameter of 40 mm. The
lesion depth ranged from 5 mm to 130 mm, with a mean
depth of 51.9¡20.9 mm and a median depth of 52 mm. For
FNAB and cutting-needle biopsy, lesion contours were
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irregular in 96 (26.5%) cases and 32 (33%) cases, speculated
in 38 (10.5%) cases and 14 (14.4%) cases, smooth in 37
(10.2%) cases and 12 (12.4%) cases, and lobulated in 22
(6.0%) cases and 8 (8.2%) cases, respectively. Information on
lesion contour was not available in 188 (41%) cases.
Adequate biopsy samples were obtained in 398 (86.7%)
cases, including 94 (96.9%) cutting-needle biopsies and 304
(84%) FNABs (p= 0.045). The incidence of biopsy sample
adequacy was significantly higher among patients under-
going FNAB for primary diagnosis (n = 187, 89.0%) than
among those patients undergoing this procedure to docu-
ment possible secondary malignancies (n = 117, 80.1%,
p=0.03); no similar difference was observed in patients
undergoing cutting-needle biopsy. The adequacy of biopsy
samples did not differ according to patient sex or age.
Significantly more specific diagnoses were obtained based
on specimens collected by cutting-needle biopsy (n= 83,
87.7%) than by FNAB (n= 247, 68.2%, p=0.003) (Table 1).
For cutting-needle biopsy specimens, the diagnoses were
confirmed using histological analysis and clinical follow-up
in 78 (80.4%) cases and by surgery in 5 (5.2%) cases. These
diagnoses were considered to be definitive, and therapeutic
regimens were established. The confirmation of specific
diagnoses based on cutting-needle biopsy specimens was
not possible in 11 (11.3%) cases because the patients were no
longer being treated at our institution; in 3 (3.1%) cases, the
material was inadequate for analysis. Specific diagnoses
based on FNAB specimens were confirmed using cytologi-
cal analysis and clinical follow-up (n= 188, 51.9%) and
surgery (n= 59, 16.3%). These diagnoses were considered to
be definitive, and therapeutic regimens were established.
Confirming specific diagnoses based on FNAB specimens
was not possible in 57 (15.7%) cases because the patients
were no longer being treated at our institution; the
specimens were inadequate for analysis in 53 (15.7%) cases,
and no information was available in 5 (1.4%) cases.
Table 2 shows the success and complication rates of
FNAB and cutting-needle biopsy, using the average lesion
depth and size as references. The success rates of both
biopsy techniques were higher for larger-than-average
($40 mm) than for smaller-than-average (,40 mm) lesions
(p,0.05). The complication rate did not differ according to
lesion size among the patients undergoing FNAB; however,
the complication rate was significantly higher for smaller-
than-average lesions in patients undergoing cutting-needle
biopsy (p,0.05). The success and complication rates did not
differ between biopsy techniques according to lesion depth,
using average depth as a reference, or according to the side
of the affected lung (p.0.05). The success rate of FNAB was
higher in superior lobes than in other lobes; no similar
difference was observed for cutting-needle biopsy (Table 3).
No significant difference according to the affected lobe was
observed between the two techniques.
Complications occurred in 63 (13.8%) cases; pneu-
mothorax occurred most frequently (n = 43, 9.4%), followed
by hematoma (n = 11, 2.4%) and hemoptysis (n = 9, 2.0%)
(Table 4). The overall complication rate did not differ
between FNAB (n= 51, 14.1%) and cutting-needle biopsy
(n= 12, 12.4%, p.0.05); however, the incidence of pneu-
mothorax was significantly higher for FNAB (n= 40, 11.1%)
than for cutting-needle biopsy (n= 3, 3.1%, p,0.05), and the
incidence of pulmonary hematoma was significantly higher
for cutting-needle biopsy (n= 7, 7.2%) than for FNAB (n= 4,
1.1%, p,0.05). The rate of hemoptysis did not differ
between the two techniques. Of the 43 (9.4%) patients with
pneumothorax, only 11 (2.5%) patients, all of whom under-
went FNAB, required thoracic drainage. The complication
rate did not differ according to FNAB indication; however,
the complication rate was significantly higher among the
patients undergoing cutting-needle biopsy for primary
diagnosis (n = 18, 23.8%) than among those undergoing this
procedure for secondary diagnosis (n = 1, 4.3%, p= 0.04)
(Table 5). Complications did not differ according to patient
sex or age.
The sensitivity, specificity, and accuracy of cutting-needle
biopsy (93.8%, 97.3%, and 95.2%, respectively) were
significantly higher than those for FNAB (82.6%, 81.3%,
and 81.8%, respectively; all p,0.05). The rate of false-
negative diagnosis of malignancy was significantly higher






FNAB 304 (84) 0.045 247 (68.2) 0.003
Cutting needle 94 (96.9) 83 (85.6)
FNAB, fine-needle aspiration biopsy; n, number of lung lesions.
Table 2 - Success and complication rates of FNAB and cutting-needle biopsy according to lesion depth and size.
Success rate Complication rate
Variablea n (%) n (%) p-value n (%) p-value
FNAB Depth 0.253 0.23
#52 mm 112 (49.3) 92 (82.1) 17 (15.2)
.52 mm 115 (50.7) 101 (87.8) 24 (21.2)
Size 0.02 0.576
#40 mm 138 (49.5) 110 (79.7) 24 (17.5)
.40 mm 141 (50.5) 127 (90.1) 21 (15)
Cutting needle Depth 0.628 0.63
#52 mm 52 (96.3) 50 (96.1) 7 (13.5)
.52 mm 2 (3.7) 1 (91.7) 1 (8.3)
Size 0.047 0.04
#40 mm 21 (30) 16 (76.2) 5 (23.8)
.40 mm 49 (70) 46 (93.9) 3 (6.1)
FNAB, fine-needle aspiration biopsy; n, number of lung lesions.
aMedian size and depth were used as references.
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for FNAB (n= 45, 17%) than for cutting-needle biopsy (n= 4,
2.6%, p,0.005); no similar difference was noted for
benignity.
& DISCUSSION
Our results indicated that CT-guided PNB is a reliable
and reproducible method for diagnosing lung lesions. Using
this method yielded high success rates for collecting
adequate material for analysis and acceptable rates for
procedure-related complications. However, several impor-
tant issues related to needle type are discussed.
Avritscher et al. (11) reported that CT-guided PNB of
pulmonary hilar lesions had a sensitivity of 91.4% and an
accuracy of 92.8%, despite the procedure’s technical
difficulty. These results are similar to those we obtained
using cutting-needle biopsy. Avritscher et al. reported
higher rates of pneumothorax and chest tube drainage
compared to our findings (48% vs. 13.7% and 32% vs. 2.4%,
respectively), which are likely due to the complexity and
difficulty of accessing hilar lesions.
Large lesions usually provide more adequate samples
for analysis than do small lesions (12). Layfield et al. (13)
demonstrated that lesion location and size affect the diag-
nostic accuracy of thoracic FNAB and that the best results
are obtained for peripheral and larger lesions. In the present
study, lesions with diameters $40 mm supplied larger
amounts of adequate biopsy material, thus enabling more
specific diagnoses compared to smaller lesions using both
biopsy techniques. In contrast to our results, which indicated
that sample adequacy and success rates were not affected by
lesion contour or depth, Miller et al. (14) demonstrated that
speculated lesion contour and greater depth were predictive
of successful biopsy sample acquisition.
The lesion location in the superior lobes has been
described as predictive of FNAB success (15), which is
likely due to minimal respiratory lung motion and ease of
access (direct, regardless of the patient’s position) relative to
other lobes. Our results support this finding. Superior
lesions frequently have pleural bases and thus exhibit close-
fitting surfaces or chest wall infiltration; thus, the biopsy
needle can be introduced without transposing the pleural
space. We found that lesion location had no effect on the
success of cutting-needle biopsy.
The high success rate of cutting-needle biopsy could be
partially explained by the selection of needle type and size
according to the lesion characteristics and the patient’s
clinical condition. In the current era of personalized
medicine, in which advanced oncological treatment is based
on molecular profiling and targeted therapy, collecting
adequate tissue specimens is important. Macrobiopsies and
tissue quality from cutting needles provide more adequate
tissue samples for such purposes than do microbiopsies (i.e.,
FNABs).
Advances in oncological treatment have been based on
targeted therapy and molecular profiling. The characteriza-
tion of intratumoral heterogeneity enables the collection of
tissue specimens from regions that represent the lesion’s
most aggressive behavior. For this reason, functional/
metabolic methods have been sought that enable the
identification of the most suspicious areas within a lesion
for biopsy. Moreover, functional imaging methods, such as
diffusion-weighted imaging (DWI) and positron emission
tomography (PET)/CT, are key to achieving effective
image-guided percutaneous biopsies, obviating more inva-
sive procedures for proper diagnosis and therapeutic
planning when using cutting needles (16,17).
Several reports have demonstrated that clinical, radiolo-
gical, and procedural factors are related to the risks of
complications (18-20). Yeow et al. (21) reported a higher rate
of pneumothorax in lesions ,2 cm and deeper than 0.1-
2 cm and for procedures performed by less-experienced
radiologists. The bleeding risk was higher in lesions ,2 cm
and deeper than 2.1 cm and in the absence of pleural
effusion. In our study, no radiological lesion characteristic
predicted complications in FNAB, and only lesions,40 mm
were predictive of complications in cutting-needle biopsy.
Additionally, a skilled radiologist or a resident under the
radiologist’s supervision performed all of the biopsies in our
study, thus minimizing the effect of operator’s experience
on success and complication rates.
In the present study, the incidence of pulmonary
hematoma was higher for cutting-needle biopsy than for
FNAB; however, this difference had no major clinical
implication. This difference may be explained by the greater
damage to the net vessels of the tumor caused by cutting-
needle biopsy due to the large needle’s disruption of the
tissue sample. In agreement with our results, Khan et al. (22)
Table 3 - Success and complication rates of FNAB and cutting-needle biopsy according to lung lobe affected.
Success rate Complication rate
Lung lobe n (%) n (%) p-value n (%) p-value
FNAB Superior 136 (49.5) 124 (91.0) 0.02 19 (14.0) 0.23
Middle 27 (11.1) 21 (77.8) 2 (7.4)
Inferior 106 (39.4) 84 (79.2) 20 (18.9)
Cutting needle Superior 42 (63.4) 42 (100) 0.43 2 (4.8) 0.34
Middle 4 (6.3) 4 (100) -
Inferior 20 (30.3) 18 (90) 2 (1.0)
FNAB, fine-needle aspiration biopsy; n, number of lung lesions.
Table 4 - Distribution of complication rates for CT-guided






Pneumothorax 43 (9.4) 40 (11.1) 3 (3.1)
Hematoma 11 (2.4) 04 (1.1) 07 (7.2)
Hemoptysis 09 (2.0) 07 (1.9) 02 (2.1)
Total complications 63 (13.8) 51 (14.1) 12 (12.4)
No complications 396 (86.2) 311 (85.9) 85 (87.6)
Total sample 459 (100) 362 (100) 97 (100)
CT, computed tomography; FNAB, fine-needle aspiration biopsy; n,
number of lung lesions.
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demonstrated that the lesion contour had no significant
effect on the complication rate.
The incidence of pneumothorax was higher for FNAB
than for cutting-needle biopsy, which might be explained by
the tendency to select FNAB for lesions with difficult
approaches, including small and deep lesions and lesions
near large vessels; these situations require more time and
transfixation to obtain adequate biopsy material. In contrast
to our finding that complication rates did not differ
according to the patient’s age or sex, Geraghty et al. (23)
demonstrated that the patient’s age had a significant effect
on the rate of pneumothorax, which occurred in 153 (60.7%)
patients aged .60 years and 99 (39.3%) patients aged #60
years (p,0.02).
One way to minimize the complication rates when applying
cutting needles is to use the coaxial technique, in which the
needle passes inside a needle guide positioned toward the
tumor. Because this device reduces the number of pleural
punctures, the pneumothorax rates are similarly reduced (24).
Several study limitations should be emphasized. First, the
retrospective selection of patients examined in an oncology
center under strong presumption of malignancy clearly
introduced selection bias into our series. Second, the reasons
for needle type selection could not be evaluated because this
information was not available. Third, the nature of
procedures performed in our institution has changed over
time; several years ago, FNAB was the preferred technique
for confirming malignancy in nearly all lung lesions.
However, cutting-needle biopsy has become the preferred
technique for diagnosis and management because the
operator’s confidence with this procedure has increased.
Fourth, a pathologist was not available during biopsy
procedures, as is typical in many oncological centers in
developing countries. Thus, the numbers of thoracic
transfixations performed and the smears or specimens
collected were related to the radiologist’s experience and
the incidence of complications at the time of the procedure.
In conclusion, our results indicate that the overall
performance of cutting-needle biopsy was stronger than
that of FNAB, with no significant increase in complication
rates. Considering that biomarker profiling and targeted
therapy are important components of oncological patient
management, cutting-needle biopsy is currently used in our
center for nearly all diagnosed lung lesions. FNAB is
reserved for patients with coagulation deficits or when
malignancy documentation is required.
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